Aquestive Therapeutics, Inc.
AQST
$6.49
-$0.20-2.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.38% | 5.29% | 13.80% | 22.56% | 25.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.38% | 5.29% | 13.80% | 22.56% | 25.45% |
| Cost of Revenue | -6.64% | -16.35% | -14.20% | -15.97% | -13.59% |
| Gross Profit | -32.54% | 19.58% | 33.40% | 53.63% | 58.38% |
| SG&A Expenses | 53.70% | 67.40% | 58.05% | 28.55% | -0.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.52% | 34.46% | 34.48% | 14.35% | -1.80% |
| Operating Income | -246.29% | -111.67% | -103.75% | 3.66% | 46.48% |
| Income Before Tax | -152.57% | -90.22% | -479.03% | -193.24% | -15.36% |
| Income Tax Expenses | 64.10% | -105.71% | -105.71% | -29.86% | -113.73% |
| Earnings from Continuing Operations | -152.89% | -88.55% | -460.83% | -190.59% | -13.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.89% | -88.55% | -460.83% | -190.59% | -13.74% |
| EBIT | -246.29% | -111.67% | -103.75% | 3.66% | 46.48% |
| EBITDA | -270.86% | -122.56% | -118.72% | 2.07% | 47.31% |
| EPS Basic | -93.41% | -36.54% | -378.65% | -110.44% | 14.60% |
| Normalized Basic EPS | -88.88% | -44.07% | -122.00% | -26.01% | 35.91% |
| EPS Diluted | -94.42% | -37.38% | -264.18% | -81.21% | 21.48% |
| Normalized Diluted EPS | -88.88% | -44.07% | -122.31% | -26.12% | 35.87% |
| Average Basic Shares Outstanding | 27.23% | 40.27% | 41.63% | 39.11% | 34.24% |
| Average Diluted Shares Outstanding | 27.23% | 40.27% | 31.85% | 29.01% | 24.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |